Company intelligence / Profile preview

TOLREMO therapeutics

Ownership: Private
Employees: ~5
Development stage: Other

Overview

TOLREMO is advancing TT125-802, an orally available small molecule CBP/p300 bromodomain inhibitor, into Phase 1 monotherapy dose escalation studies to evaluate safety, pharmacokinetics, pharmacodynamics, and early signs of efficacy in solid tumor indications[4]

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

TT125-802

Beyond the preview

Go deeper on TOLREMO therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TOLREMO therapeutics.